

<Organisation Details>
<Organisation Address>
<Organisation Details>

<Today's date>

<Patient Name>
<Patient Address>

Dear <Patient Name>

DOB: <Date of Birth> NHS No: <NHS number>

Subject: Denosumab injections

We are writing to inform you of an important update regarding your prescription for Denosumab.

You receive a 6-monthly injection of a medicine called Denosumab, used to treat bone loss and osteoporosis. It belongs to a group of medicines called monoclonal antibodies and is given by an injection under the skin (subcutaneous).

Denosumab is a biological medicine which means it is not made using traditional chemical laboratory processes. Biological medicines have been used in the UK for over 20 years and have improved the lives of millions of patients, however they are very expensive.

Until recently, only one pharmaceutical company (Amgen) made denosumab. Now other companies can make 'biosimilar' versions which have the same quality, safety and effectiveness profile as the original drug, but are better value for the NHS which means more patients can receive treatment.

In line with NHS England recommendations, your prescription has been updated from the original brand (Prolia) to a Dorset formulary first choice, biosimilar) product.

If you have any questions regarding this change, please discuss with your GP practice team.

Yours sincerely

<GP Name>
<Organisation Details>